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Abstract
Background: Evidence shows that internet-based self-help interventions are effective in reducing symptoms for a
wide range of mental disorders. To date, online interventions treating psychotic disorders have been scarce, even
though psychosis is among the most burdensome disorders worldwide. Furthermore, the implementation of
cognitive-behavioral therapy (CBT) for psychosis in routine health care is challenging. Internet-based interventions
could narrow this treatment gap. Thus, a comprehensive CBT-based online self-help intervention for people with
psychosis has been developed. The aim of this study is the evaluation of the feasibility and efficacy of the
intervention compared with a waiting list control group.
Methods: The intervention includes modules on delusion, voice hearing, social competence, mindfulness, and
seven other domains. Participants are guided through the program by a personal moderator. Usage can be
amended by an optional smartphone app. In this randomized controlled trial, participants are allocated to a waiting
list or an intervention of eight weeks. Change in positive psychotic symptoms of both groups will be compared
(primary outcome) and predictors of treatment effects will be assessed.
Discussion: To our knowledge, this project is one of the first large-scale investigations of an internet-based intervention for
people with psychosis. It may thus be a further step to broaden treatment options for people suffering from this disorder.
Trial registration: NCT02974400 (clinicaltrials.gov), date of registration: November 28th 2016.
Keywords: Online intervention, CBT, Psychosis, Schizophrenia, Internet, Guided self-help
Background
Schizophrenia and other psychotic disorders are severe
mental disorders with heterogeneous symptom profiles
encompassing positive symptoms such as persecutory
delusions and auditory verbal hallucinations as well as
negative symptoms such as social isolation and avolition
[1]. In addition, they are accompanied by neuropsycho-
logical impairments in attention, memory, and executive
functioning [2–6]. Sleep is impaired in the majority of
people experiencing persecutory delusions [7] and levels
of worrying are high [8, 9]. Besides symptoms,
stigmatization is a major source of distress in people
diagnosed with schizophrenia [10], even in the context
of mental health care [11]. Lifetime prevalence of schizo-
phrenia is about 1% and stable across different regions
of the world and cultures [12]. Schizophrenia is accom-
panied by an enormous individual and societal burden
[13, 14] and lies on position eight of the leading causes
of disability-adjusted life years in 15- to 44-year-olds
[15]. About 65% of individuals with a first episode re-
lapse during the subsequent three years [16], resulting in
inpatient costs about two to five times higher compared
to non-relapsed patients [17].
As a complementary or alternative treatment option to
antipsychotic medication [18], cognitive behavioral ther-
apy for psychosis (CBTp) has emerged as an evidence-
based treatment option for patients with schizophrenia
and related disorders [19–24]. CBTp targets psycho-
logical mechanisms of symptom formation and mainten-
ance that were primarily identified or corroborated using
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experimental psychopathology research [25–27]. The
therapeutic framework and techniques of CBTp are to a
large extent similar to those of cognitive behavioral ther-
apy (CBT) for depressive or anxiety disorders (cognitive
restructuring, reality testing, etc.). For example, the dis-
tress (consequence) related to hearing voices (situation)
is assumed to be determined not by hearing voices per
se, but predominantly by automatic thoughts and the
according belief system. Consequently, alternative help-
ful beliefs about voices established with the help of cog-
nitive techniques are supposed to result in less distress
[28]. CBTp is likely to be effective for patients who
choose not to take antipsychotic medication, too [29]. In
regular mental health care, the effectiveness of CBTp
has also been asserted [30], and neurocognitive deficits,
comorbidity and poorer functioning pose no barrier to
improvement during CBTp [28]. Consequently, national
regulations such as the United Kingdom National Insti-
tute for Health and Care Excellence (NICE) guideline
recommend that CBTp should be offered to every per-
son with psychotic symptoms [31].
Acceptance and Commitment Therapy (ACT) focuses
on noticing rather than changing thoughts and feelings
[32]. ACT seems to be effective in treating mental health
problems [33]. In schizophrenia, ACT helps people to
cope with psychotic experiences using strategies such as
cognitive distancing, which is characterized by learning
to see one’s belief as a hypothetical statement rather
than a fact. Instead of trying to change, modify, or con-
trol odd cognitions or disturbing sensory states, patients
are encouraged to instead simply be aware of these
experiences [34]. A meta-analysis showed a medium-
sized effect of ACT on symptoms of psychosis [35].
The third type of treatment is the Metacognitive Train-
ing for psychosis (MCT), developed specifically for people
with schizophrenia [36, 37]. MCT invites participants to
critically evaluate cognitive biases such as jumping to con-
clusions and overconfidence in their thinking (metacogni-
tion). These biases might increase the likelihood of
psychotic symptoms [38]. Studies show that MCT is
efficacious in reducing psychotic symptoms [39, 40].
Despite the availability of evidence-based treatments
for schizophrenia, 69% of patients remain untreated in
countries with low and middle income [41]. In particu-
lar, the need for psychosocial treatments including CBTp
remains unmet [42]. Even in highly developed countries
such as the United Kingdom or Germany, the treatment
gap for schizophrenia is large. In theory, the NICE
guidelines proclaim that CBTp is mandatory for the
treatment of psychosis [31]. In practice, more than 50%
do not receive even a single session of CBTp [43]. In
Germany, CBTp is virtually not represented in the
mental health service [44]. To sum up, CBTp is effective,
recommended, and has great potential to alleviate
psychological distress, but only a small fraction of pa-
tients with psychosis receives CBTp.
Internet-based cognitive behavioral therapy (iCBT) can
help to overcome treatment gaps in many mental disor-
ders [45]. In several psychological disorders, including
anxiety and depression, internet-based treatments have
proven to be efficacious and effective in randomized con-
trolled trials (RCTs; for a comprehensive review, see [46]).
Most of the growing body of evidence comes from studies
evaluating guided internet-based self-help treatments.
While patients work their way through a structured self-
help program that is typically based on CBT manuals,
therapists or coaches assist and support them via a
secured e-mail system. Meta-analyses on internet-based
treatments show a superiority of guided interventions in
comparison to unguided, automated programs in terms of
efficacy, adherence to treatment, and drop-out rates
[47–49]. Main advantages of guided internet-based
treatments include: (1) low-threshold accessibility, (2)
flexible usage independent of time and place at a self-
determined pace, (3) high levels of anonymity and privacy
(which is an attractive feature for many persons with a
mental disorder due to their fear of stigmatization) and (4)
low costs of delivery to large populations [50].
People diagnosed with schizophrenia use the internet
[51] and are able and willing to use mental health ser-
vices on the internet, such as peer-to-peer support [52].
The feasibility of internet-based treatments for people
with psychosis (iCBTp) is well documented for web-
based interventions [53, 54] and also reported for smart-
phone interventions [55]. However, current internet-
based programs differ in their comprehensiveness and
focus. For instance, mixed results have been reported
regarding the efficacy of internet-based psychoeducation
programs [56], and the efficiency of internet-based pro-
grams targeting medication management [53, 57]. There
is a pilot study on a more comprehensive web-based,
CBTp-oriented program for auditory verbal hallucina-
tions, but this program was delivered via computers in
mental health care centres (and not online). The study
provided promising results using an uncontrolled pre-post-
design (Cohen’s d = 0.58) [58]. None of the 21 participants
with schizophrenia reported that the program was unhelp-
ful and the authors report no adverse events, highlighting
the feasibility of iCBTp in a computerized self-help format.
A recent investigation of aforementioned program in an
RCT design showed a comparable effect of the web-based
intervention and usual care on levels of auditory hallucina-
tions [59]. The study was able to show that patients with
schizophrenia who used the web-based program, however,
had increased significantly in social functioning and their
knowledge about CBTp was larger than of those who did
not use the program. In another study that investigated
iCBT for people with schizophrenia, the web-based
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program specifically targeted comorbid depressive symp-
toms. The intervention lead to a significant decline in de-
pression severity [60].
In summary, there is preliminary evidence that iCBTp
for people diagnosed with schizophrenia could be bene-
ficial. However, to the best of our knowledge, no larger
trials on comprehensive treatments have been con-
ducted. The overarching goal of this RCT is to evaluate
a guided internet-based self-help intervention for people
with psychosis. We developed a web-based program that
is comprehensive in many respects: The program is not
only based on CBT but also includes elements from its
third wave, specifically ACT and MCT [34, 36]. Schizo-
phrenia patients often have comorbidities, such as de-
pression, which should be addressed in an appropriate
treatment [61]. This program offers additional interven-
tions for such comorbidities. Disrupted sleep and worry-
ing, among other secondary symptoms, are crucial in
the formation and maintenance of psychotic disorders
[25]. These factors are considered in the intervention as
well. According to a review, the effects of smartphone-
enhanced self-help are promising [62]. The intervention
therefore includes an accompanying smartphone app for
access in symptom-relevant situations in daily life. The
app is expected to facilitate a transfer of skills to real
world settings. Finally, a specific goal of the intervention
was not to overstate negative consequences of the dis-
order [63] and solely focus on deficits, but to specifically
target resources of the participants [64].
Treatment adherence in schizophrenia has been a well
discussed topic predominantly in medication treatment
[65]. But also in psychological treatments, rather high
dropout rates are reported (e.g. prematurely terminated
treatments by 45% of patients) [66]. This led us to look
for factors that might influence treatment adherence.
Among others, suggested mediators are treatment mo-
tivation [67] and working alliance with the therapist
[68]. Overall, the study tests whether a comprehensive
internet-based self-help program with an accompanying
smartphone app reduces symptomatology in people with
schizophrenia.
Methods
Study design
The study is an RCT of parallel design comparing the
efficacy of guided internet-based self-help treatment for
patients with schizophrenia to a waiting list control
group (Fig. 1). Participants in the control group receive
access to treatment after the intervention period of eight
weeks. The long-term effect of the intervention is mea-
sured by a follow-up assessment six months after the
intervention period has ended and is not part of the RCT
design.
Sample size
A power analysis with the software G*Power [69] resulted
in a target sample size of 128 to detect a medium-sized
effect (f = 0.25) with α = 0.05 and a power of 0.80 for an
ANCOVA. Including an assumed attrition rate of about
10%, the final number of participants should reach 140.
Fig. 1 Participant flow
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Recruitment
Participants will be recruited in three different ways:
First, the study staff will contact former patients with
diagnoses of schizophrenia who consented to get con-
tacted and inquire whether they are interested in partici-
pating in this study via e-mail. Second, study information
will be sent out to psychiatric institutions in Switzerland
and Germany. The health staff at those institutions can
then distribute the information to interested and suitable
patients directly, for example those patients who leave the
institution and look for a continuation treatment. Lastly,
online bulletin boards and informative websites on psy-
choeducation specifically created for people affected by
schizophrenia will be targeted for publishing descriptions
and links to the study.
Eligibility criteria
To be included, participants must fulfill all inclusion
criteria and not show any exclusion criteria described
below. Suffering from other psychiatric disorders such as
depression or anxiety disorders (part of the former ‘axis
I’ disorders) does not lead to exclusion as long as the
schizophrenia spectrum disorder is the primary
diagnosis.
Inclusion criteria are:
1 An age of 18 years or older.
2 Provision of electronic informed consent.
3 Access to the internet.
4 Command of the German language.
5 Fulfilling the diagnostic criteria for either
schizophrenia, delusional disorder or schizoaffective
disorder in their lifetime according to the structured
Mini International Neuropsychiatric Interview
(MINI) [70] administered during a telephone
interview. These diagnoses are allowed to be partly
remitted.
6 A score of three or higher on the items assessing
delusions (P1), hallucinations (P3) or suspiciousness/
persecution (P6) on the Positive and Negative
Syndrome Scale (PANSS) [71] showing that some
positive symptoms remain.
7 Simultaneous treatment with antipsychotic
medication (or regular psychological or psychiatric
care in Germany).
Exclusion criteria are:
1 Acute suicidality.
2 Representing an acute danger for others.
3 No agreement on compiling an emergency plan.
4 Diagnosis of an acute neurological disease of the
central nervous system that needs to be treated.
Randomization
Participants eligible for inclusion will be randomly allo-
cated to one of the two groups (intervention or waiting
list control group). Randomization and allocation will be
prepared in advance by an independent researcher. This
researcher will remain blinded to all processes within the
intervention. An automated, web-based randomization
service (www.random.org) [72] will be used to generate
the randomization list. The allocation ratio will be 1:1.
Intervention
The intervention called EviBaS (for Evidence-Based Self-
help intervention) consists of an online program based
on CBT principles, while also including components of
ACT and MCT treatments. A smartphone app provides
the possibility of exercising the modules in everyday life.
Table 1 Modules of the online program EviBaS
Name Description
Introduction Reflect on thoughts, feelings and behavior to understand and decrease the symptom burden.
Feelings of Threat Review the effects of paranoia on individual goals and needs.
Voice Hearing Learn strategies to reduce distress caused by hearing voices (better coping, influence the
evaluation of voices).
Self-Worth Find forgotten strengths and train a balanced sense of self.
Overcoming Depression Set up activities and scrutinize depressing thoughts.
Worrying Minimize upholding factors of worry and tackle worries with problem solving skills.
Sleep Discuss maintaining factors of the sleep disorder, such as sleep hindering thoughts or
disadvantageous surrounding factors.
Mindfulness Exercise to direct your attention on one thing without judgement.
Metacognition Learn in interactive exercises to avoid jumping to conclusions and overconfidence in errors.
Social Competence Plan and train three different types of social situations: enforcing interests, shaping
relationships, and winning sympathies.
Relapse Prevention Collect individual warning signs and plan ahead.
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There are 11 text-based modules in the online program,
addressing a variety of topics (see Table 1). Each module
includes texts and a worksheet. The worksheets can also
be accessed via the optional app. The only mandatory
module is the introductory one. After completion, the par-
ticipants can choose from the remaining ten modules
freely. Relapse prevention is recommended as the last
module. Study participants are asked to work on approxi-
mately one to two modules per week. The time required
to finish one module may vary, but will usually not exceed
60 min. The intervention is self-paced, so that participants
are able to work on topics they prioritize, such as emo-
tional issues rather than positive symptomatology [73].
While working with the program, participants will be in
contact with a personal moderator if they want to. The
moderator will guide the participants through the pro-
gram with at least one message per week. The main goal
of this steady contact is to help participants structure their
usage of the program and to encourage regular participa-
tion [47]. If necessary (in case of a participant not using
the intervention for seven days), the moderator reminds
the participant to interact with the program. Participants’
questions are answered within three workdays by modera-
tors. There is a biweekly supervision of all the moderators
in the study team led by a licenced psychotherapist with
extensive experience in CBTp.
Measures
The primary outcome is the reduction of psychotic symp-
toms (positive symptoms such as voice hearing and para-
noid delusions) at post assessment (directly after the
completion of the intervention). Secondary outcomes in-
clude the level of symptomatology at follow-up, the number
of dropouts and the results of all secondary questionnaires
which evaluate quality of life, depression severity, treatment
satisfaction, the influence of treatment expectancy, and
process measures, among others (see Table 2). Assessments
will be completed at baseline, eight weeks and 32 weeks.
For an overview of all primary and secondary outcome
measures, predictors and moderators, as well as process
measures, see Table 2.
Primary outcome measures
Positive and Negative Syndrome Scale (PANSS)
The PANSS [71] was the first standardized evaluation tool
for symptoms of schizophrenia [74]. It assesses 30 symp-
toms, which can be grouped into five factors: positive
symptoms, negative symptoms, disorganization, excite-
ment, and emotional distress [1]. The positive symptom
factor serves as the primary outcome of this study. It
includes nine items (delusions, hallucinations, unusual
thought content, suspiciousness, grandiosity, somatic con-
cern, active social avoidance, lack of judgment and insight,
and (less) difficulty in abstraction). In this study, clinicians
administer the PANSS via telephone.
MINI International Neuropsychiatric Interview (MINI)
The MINI is a diagnostic structured interview for the as-
sessment of psychiatric diagnoses [70], with a corre-
sponding German version [75]. The specificity of the
MINI was reported as good for all diagnoses (ranging
from 0.72 to 0.97) [70]. In this study, a part of the MINI
(depressive episode, suicidality, manic episode, and
psychosis) was also administered via telephone.
Paranoia Checklist
The Paranoia Checklist was developed by Freeman et
al. in 2005 [76] and assesses the frequency, degree of
conviction, and associated distress of a wide range of
paranoid thoughts. The three subscales each include
the same 18 items, which are rated on a five-point
Likert scale: The first subscale measures the frequency
of paranoid thoughts (ranging from ‘does not apply at
all’ to ‘applies very well’; adapted), the second subscale
measures the degree of conviction (from ‘not at all con-
vinced’ to ‘absolutely convinced’) and the third subscale
surveys the level of distress (from ‘not distressing’ to
‘very distressing’). Cronbach’s alpha, as an estimate of
reliability, is reported as .90 or above, which stands for
an excellent internal consistency of the Paranoia
Checklist [76].
Launay–Slade Hallucination Scale (LSHS-R)
The LSHS-R is the revised version of the LSHS, devel-
oped by Launay and Slade in 1981 [77]. It includes 12
items and measures the predisposition to hallucinations
on a wide spectrum [78]. There is a German version of
the LSHS-R, which shows a Cronbach’s alpha of .87 in a
patient sample and therefore is comparable to the ori-
ginal [79]. The five-point Likert scale ranges from 0
(‘certainly does not apply to me’) to 4 (‘certainly applies
to me’) and there is a sum score that will be compared
between both groups of participants.
Secondary outcome measures
Delusion and Voices Self-Assessment (DV-SA)
The DV-SA has two subscales, a Delusions Scale (DS)
and a Voices Scale (VS). The former contains five items
to assess patients' opinions about the dominant delu-
sional idea and the latter includes ten items about the
subjective dimensions of auditory hallucinations [80].
All responses of the participants are rated on two four-
point Likert scales, from 0 (absence of problems) to 3
(the severest of problems), with the highest achievable
total score of 15 for the DS and 33 for the VS [80]. For
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this study, we changed the time period referenced in
the DV-SA from 1 month to 1 week.
Incongruence questionnaire (K-INK)
The K-INK [81] is a short version of a questionnaire
(INK) that measures the degree of realization of
motivational goals in the participant’s life. Those goals
can be classified into two groups: approach goals and
avoidance goals. On a five-point Likert scale, the K-
INK measures approach incongruence, avoidance
incongruence, and total incongruence. Internal
consistency (as measured by Cronbach’s alpha) for
the K-INK is reported as ranging between .52 and
.87 [81].
Table 2 An internet-based intervention for people with psychosis (EviBaS): Schedule of enrolment, intervention and assessments
Study period
Enrolment Allocation Post-allocation Close-out
Timepoint t-1 t0 t1 intervention/
waiting period
t2 post
assessment
t3 follow-up
assessment
Eligibility screen X
Informed consent X
Allocation X
Interventions:
EviBaS intervention group X
Waiting list control group X
Assessments:
Primary outcome measures
Positive and Negative Syndrome Scale (PANSS) X X X
Mini International Neuropsychiatric Interview (MINI) X X X
Paranoia Checklist X X X
Launay–Slade Hallucination Scale (LSHS-R) X X X
Secondary outcome measures
Delusion and Voices Self-Assessment (DV-SA) X X X
Rosenberg Self-Esteem Scale (RSES) X X X
Insomnia Severity Index (ISI) X X X
Penn State Worry Questionnaire - Abbreviated (PSWQ-A) X X X
Patient Health Questionnaire (PHQ-9) X X X
Box Task X X X
Mindful Attention Awareness Scale (MAAS) X X X
Interpersonal Competence Questionnaire (ICQ; subscales
initiation and negative assertion)
X X X
Incongruence questionnaire (K-INK) X X X
World Health Organization Quality of Life Assessment (WHO-QoL-BREF) X X X
Internalized Stigma of Mental Illness – short version (ISMI) X X X
Predictors and moderators
Medication Adherence Rating Scale (MARS-D) X X X
Attitudes towards Psychological Online Interventions (APOI) X
Credibility/Expectancy Questionnaire (CEQ) X
University of Rhode Island Change Assessment (URICA) X
Client Satisfaction Questionnaire (CSQ) X
Questionnaire Side Effects Psychosis and Internet (QueSPI) X
Process measures
Working Alliance Inventory – Short Revised (WAI-SR) X
Intermediate Assessments Questionnaire X
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World Health Organization Quality of Life Assessment
(WHO-QoL-BREF)
The WHO-QoL-BREF consists of 26 items and is a
standard questionnaire to measure the quality of life
[82]. Cronbach’s alpha values range from .66 to .84, indi-
cating an acceptable internal consistency [82]. The
WHO-QoL-BREF demonstrates good discriminant valid-
ity [82]. In this study, it is administered both in baseline
and post assessments and the participants have to indi-
cate their level of agreement on a five-point rating scale
with changing answer formats.
Rosenberg Self-Esteem Scale (RSES)
The RSES measures self-esteem on a four-point Likert
scale. The RSES shows a high reliability and validity for
global self-worth [83]. It demonstrates an excellent in-
ternal consistency (Guttman scale coefficient of repro-
ducibility of .92) [84]. Moreover, the two week test-retest
reliability revealed high correlations of .85 and .88, indi-
cating excellent stability [84]. Higher scores on the RSES
indicate higher self-esteem.
Insomnia Severity Index (ISI)
The ISI is a brief measure for insomnia and is composed
of seven items. Each of these items is rated on a five-
point Likert scale, ranging from 0 (‘not at all’) to 4 (‘ex-
tremely’). Studies reported adequate psychometric prop-
erties for ISI versions in English and French [85, 86].
Penn State Worry Questionnaire - Abbreviated (PSWQ-A)
The PSWQ [87] is a questionnaire designed to assess
the tendency to worry. In this study, an abbreviated
eight-item version (PSWQ-A) was used [88]. The meas-
ure is scored on a five-point Likert scale from 1 (‘not at
all typical’) to 5 (‘very typical’). The PSWQ-A items have
good internal consistency highlighted by reported Cron-
bach’s alpha ranging from .87 to .89 and .94 [88, 89].
Scores for the PSWQ-A range from 8 to 40 [90].
Patient Health Questionnaire (PHQ-9)
The PHQ-9 measures depression severity [91]. It scores
all nine DSM-IV criteria for depression on a rating scale
from 0 (‘not at all’) to 3 (‘nearly every day’). A score of
20 represents severe depression. Internal consistency of
the PHQ-9 is excellent with a Cronbach’s alpha of
between 0.86 and 0.89 [91]. In this study, the short Ger-
man version (PHQ-D) was used [92] and the item on
suicidality also serves as an indication of the necessity of
exclusion from the study.
Box Task
In the Box Task [93], participants are confronted with
grey boxes on the computer screen, concealing two
distinct colours. Participants have to gather information
about which of the two colours is more frequent by
clicking on said boxes. When they decide that they have
gathered sufficient information, they can choose the
more frequent colour. This experimental paradigm has
been administered in a previous study [94]. If the
amount of information an individual gathers before
making a decision is low this indicates a tendency to
jump to conclusions [27]. Jumping to conclusions has
been found to be associated with schizophrenia and de-
lusions [95].
Mindful Attention Awareness Scale (MAAS)
The MAAS is a questionnaire measuring mindfulness on
a six-point Likert scale. Cronbach’s alpha of the MAAS
has been reported as .81 [96].
Interpersonal Competence Questionnaire (ICQ)
The ICQ is originally a 40-item questionnaire for the as-
sessment of five domains of interpersonal competence
[97]. In this study, only two of the five domains are sur-
veyed: initiation of relationships and negative assertion.
Moreover, a recently published short version of the ICQ
(called ICQ-15) [98] was used to pick out the six items
of the two subscales (three for each domain). The in-
ternal consistency of the total scale was high (Cronbach’s
alpha = .87) and the reliability coefficients of the sub-
scales were the highest two coefficients of the five sub-
scales: .73 (for initiation of relationships) and .75 (for
negative assertion) [98]. The German version of this
questionnaire has been validated as well [99].
Internalized Stigma of Mental Illness (ISMI) – Short version
The ISMI is a questionnaire measuring the internalized
stigma of participants [100]. In this study, the short
version of the ISMI was used, which includes 10 items
with four-point Likert scales [101]. To evaluate the re-
sults, one calculates the mean of those items. A mean
score between 1.00 and 2.50 points stands for no inter-
nalized stigma, while a mean score between 2.51 and
4.00 stands for high internalized stigma. The German
version of the ISMI showed a high internal consistency
(Cronbach’s alpha = .92), which was calculated in a study
with 139 participants [102].
Predictors and moderators
Medication Adherence Rating Scale (MARS-D)
The MARS [103] consists of five items rated on a
five-point Likert scale. These items measure a partici-
pant's non-adherent behavior from 1 (‘always’) to 5
(‘never’). A higher score indicates higher adherence to
the prescribed medication. MARS-D is the German
adaption of this questionnaire developed by Mahler et
al. [104]. Internal consistency of the MARS-D
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(Cronbach’s alpha ranging from .60 to .69) was re-
ported as satisfactory and comparable to the original
[104].
Attitudes towards Psychological Online Interventions (APOI)
The APOI measures patients’ attitudes towards an online
intervention [105]. It reveals certain prejudgments of a
study participant, which might influence the outcome
parameters and the motivation. Sixteen items are displayed
and the level of agreement with each item can be indicated
on a five-point rating scale (ranging from ‘no agreement’ to
‘total agreement’). A factor analysis of the APOI showed
four dimensions: (a) scepticism and perception of risks (b)
confidence in effectiveness (c) technologization threat and
(d) anonymity benefits. The APOI shows acceptable to
good internal consistency and a good content validity is as-
sumed, because the construction of items was done deduct-
ively as well as inductively [105].
Credibility/Expectancy Questionnaire (CEQ)
The CEQ is an economic scale to measure treatment ex-
pectancy and rationale credibility [106]. The dimensions
measured by the CEQ can possibly moderate the out-
come. In this study, participants rate items according to
two dimensions - one dimension is related to thinking
and one is related to feeling. On four of six items, the rat-
ing scale ranges from ‘no agreement’ to the treatment ra-
tionale to ‘total agreement’ on a nine-point rating scale.
For the remaining two items, participants can indicate the
subjective symptom improvement from 0% to 100% in
steps of 10%. The CEQ demonstrated a high internal
consistency of between .84 and .85 [106].
University of Rhode Island Change Assessment (URICA)
The URICA [107] is a measure of readiness to change.
The 32-item URICA consists of four subscales (eight
items each) that correspond to four stages of change
(precontemplation, contemplation, action and mainten-
ance) [108]. Internal consistency for the total URICA
was reported as excellent (Cronbach’s alpha = .83) [109].
This study used a short version of the German URICA
(URICA-S) [110], where items are rated on a five-point
Likert scale ranging from 1 (‘not applicable at all’) to 5
(‘very applicable’).
Client Satisfaction Questionnaire (CSQ)
The CSQ asks participants to what extent they were satis-
fied with the intervention [111]. The internal consistency of
the CSQ was .93, which stands for an excellent score. There
is evidence for a strong construct validity of the CSQ as
well [111]. Because it measures treatment satisfaction, it
can only be administered at post assessment. Due to its
shortness and comprehensiveness, the CSQ is very suitable
for mailed surveys [112] and can therefore also be
administrated in an online format. The German version
(called ZUF-8) [113] is being used in this current study.
The eight items can be answered on a four-point rating
scale [113].
Questionnaire about Side Effects Psychosis and Internet
(QueSPI)
This questionnaire assesses the negative effects of internet-
based interventions for psychotic patients. It was developed
within the research group as part of a pilot study leading
up to the current project [114]. Detailed information can
be found in the Additional file 1.
Process measures
Working Alliance Inventory – Short Revised (WAI-SR)
As a measure of the weekly variation of the therapeutic
alliance, the WAI-SR [114] was included in the study in
its German version [115]. It goes back to the Working
Alliance Inventory (WAI) [116] and differentiates between
goal, task and bond alliance dimensions. Each of those di-
mensions is represented by four items. The WAI-SR uses
a five-point rating scale representing the frequency of
positive alliance experiences (ranging from ‘rarely’ to ‘al-
ways’). Cronbach’s alpha of the subscale scores ranges
from .85 to .90, and of the total scores from .91 to .92, in-
dicating excellent internal consistency [114].
Intermediate Assessments Questionnaire
The study group designed a questionnaire to briefly meas-
ure symptoms and mental states that were expected to
change over the course of the online intervention. Each
therapeutic topic covered in the online intervention is rep-
resented by a single item in the intermediate assessments
questionnaire, such as auditory hallucinations, quality of
sleep, self-worth, worry, or depression. Additionally, po-
tentially psychosis-related thinking styles (e.g. jumping to
conclusions) are assessed via single items. Five out of 14
items were newly created by the authors, the remaining 9
items were adopted from German versions of established
questionnaires (e.g. PHQ-9) [117], or taken and translated
from experience sampling studies on schizophrenia (e.g. ‘I
feel suspicious‘) [118]. The intermediate assessments
questionnaire uses a five-point rating scale ranging from
‘not at all true’ to ‘absolutely true’ and can be read in the
Additional file 2.
Data collection and management
At baseline, participants complete an online assessment in-
cluding several questionnaires described above. An elec-
tronic informed consent and demographic questions will be
displayed at the beginning of this online survey. Participants
must also indicate their e-mail address and telephone num-
ber, which are processed independently from other data.
The process of baseline assessment lasts approximately 35
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to 40 min. After completion and if no inclusion criteria is
not met, a telephone interview with the participant will be
arranged. This telephone interview includes two diagnostic
interviews (MINI and PANSS, also described above) and the
development of an individual emergency plan in case of
acute suicidality or psychotic relapse with each participant.
The interview lasts approximately 45 to 60 min. If the
participant scores below the cutoff on all of the PANSS
items (delusions, hallucinations or suspiciousness/persecu-
tion), or if the participant reports neither current nor past
psychotic symptoms, he or she is excluded from participa-
tion and receives a short self-help manual as a compensa-
tion for the assessment participation. When inclusion
criteria are met, the participants are randomized to one of
two groups. The participant either gets access to the online
intervention program immediately or after a waiting period
of eight weeks. After completion of the intervention period,
post assessment and a second telephone interview are ad-
ministered. The same procedure takes place during the
follow-up assessment six months after the intervention
period.
Statistical analyses
Based on the intention to treat sample, a linear mixed-
model repeated measures ANOVA with time (T1-T2) as
a within-group factor and study condition as a between-
group factor will be used for the main research question.
Mixed-model repeated measures ANOVA uses all avail-
able data of each subject and does not require the sub-
stitution of missing values. Sensitivity analysis will be
conducted to analyze the impact of dropout on the re-
sults. The significance level is set at 5%. We are also in-
terested in possible mediators and/or moderators of the
relation between the internet-based self-help interven-
tion and positive psychotic symptoms. We will therefore
test whether predictors identified in the literature, such
as treatment motivation, working alliance or usage of
the intervention could mediate and/or moderate the
main effect [119]. To evaluate these possible predictors
of treatment outcome, we use change scores of outcome
measures as the dependent variables.
Ethical aspects and data safety
The Cantonal Ethics Committee Bern (ID: 03/14) as well as
the German Society for Psychology (ID: SM052015_CH)
have approved of this study. Data safety is ensured by
several means: The program and app usage are independ-
ent of any personal data. Conversely, the communication
via the secured e-mail system contains no information that
would allow the identification of a participant in EviBaS.
Sensitive data (where personal information such as the e-
mail address can be linked to login data for the online pro-
gram) is stored exclusively non-electronically in a locked
closet at one study site. Diagnostic staff will not know the
identification of the participants in the program and will be
blinded for the allocation of participants in the two groups,
whereas moderating staff will not know the contact infor-
mation of the participants. Breach of blinding will be re-
ported. Network security is achieved through SSL
encryption. All staff members who are in contact with study
participants, are required to fill out a non-disclosure
agreement.
Discussion
EviBaS has been developed as one of the first fully encom-
passing iCBT programs for people with psychosis. People
with schizophrenia spectrum disorders suffer from a heavy
burden of symptoms and stigmatization [13]. Psychological
evidence-based treatments for schizophrenia exist, but only
a small portion of affected people receive them [120].
Bridging the treatment gap in the psychological care for
people with severe mental disorders is therefore of utmost
importance. This project wants to reach people who do not
receive psychological treatment but are looking for support.
Internet-based interventions might even be able to reach a
group of patients that discontinued a previous face-to-face
therapy [121]. Given the efficacy of CBTp on hallucinations
and delusions [122], as well as of iCBT in other mental dis-
orders [46], the EviBaS self-help program is expected to re-
duce symptomatology. Negative effects and long-lasting
effects of the treatment will be assessed. This study will also
add to our understanding of how people with schizophrenia
use internet-based interventions.
Additional files
Additional file 1: Questionnaire about Side Effects Psychosis and
Internet (QueSPI). (DOCX 20 kb)
Additional file 2: Intermediate Assessments Questionnaire. (DOCX 12 kb)
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